Germline mutations in the MLH1 gene and aberrant MLH1 promoter methylation result in a deficiency of the MMR pathway and an increased risk of developing numerous cancers, including nonpolyposis colorectal cancer (Lynch syndrome), endometrial, and ovarian cancers [6]. This evidence concerns the gene MLH1 and ovarian carcinoma.